Brain injury and concussion assessment
SANUWAVE is a shockwave technology company developing patented, noninvasive devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead product, the dermaPACE System, is FDA Cleared for the treatment of Diabetic Foot Ulcers (DFU) in the United States.
For International Markets, the dermaPACE System is CE Marked for use on acute and chronic defects of the skin and subcutaneous soft tissue.
Pulsed Acoustic Cellular Expression (PACE®) is SANUWAVE’s proprietary form of Extracorporeal Shock Wave Therapy (ESWT). PACE® utilizes high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures to elicit a series of biological responses.
PACE® treatment results in an increase in perfusion and arteriogenesis, biofilm disruption, a pro-inflammatory response, cytokine and chemokine effects, growth factor upregulation, angiogenesis (new blood vessel formation) and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures.
The dermaPACE System is the only focused Extracorporeal Shock Wave Therapy (ESWT) cleared by the Food and Drug Administration (FDA) for the treatment of Diabetic Foot Ulcers (DFU).